UA106617C2 -
N- (hetero) arylpyrrolidine derivatives of pirazol-4-ylpyrrolo [2,3-d] pyrimidines and pyrrol-3-ylpyrrolo [2,3-d] pyrimidines as inhibitors
- Google Patents
N- (hetero) arylpyrrolidine derivatives of pirazol-4-ylpyrrolo [2,3-d] pyrimidines and pyrrol-3-ylpyrrolo [2,3-d] pyrimidines as inhibitors
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=47780587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA106617(C2)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Інсайт КорпорейшнfiledCriticalІнсайт Корпорейшн
Priority claimed from PCT/US2010/035783external-prioritypatent/WO2010135650A1/en
Publication of UA106617C2publicationCriticalpatent/UA106617C2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Цей винахід стосується N-(гетеро)арилпіролідинових похідних Формули І:, Іщо є JAK-інгібіторами, такими як селективні інгібітори JAK1, що застосовують для лікування захворювань, пов'язаних з активністю Янус-кіназ, включаючи, наприклад, запальні й аутоімунні розлади, а також рак.The present invention relates to N- (hetero) arylpyrrolidine derivatives of Formula I :, What are JAK inhibitors, such as selective JAK1 inhibitors, for use in the treatment of diseases related to Janus kinase activity, including, for example, inflammatory and autoimmune disorders, as well as cancer.
UAA201115198A2009-05-222010-05-21
N- (hetero) arylpyrrolidine derivatives of pirazol-4-ylpyrrolo [2,3-d] pyrimidines and pyrrol-3-ylpyrrolo [2,3-d] pyrimidines as inhibitors
UA106617C2
(en)
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.